Mithra Pharmaceuticals SA/NV Announces the Last Patient Enrollment in the Pharmacodynamics & Pharmacokinetics Studies of the Zoreline® Implant 10.8 mg

,

Liège, Belgium 18 November 2015 – Regulated information:  Mithra Pharmaceuticals, leader in Women’s Health and cutting-edge technological company in the field of API slow-release drugs based on polymere (subcutaneous implants, biocompatible rings, hormonal IUD’s), announced today that it has enrolled the last patient required in the pharmacodynamics & pharmacokinetics studies of its Zoreline® subcutaneous implant 10.8 mg.

Read the press release

Mithra Pharmaceuticals Invests EUR 75.2 Million in Flemalle

Flémalle, Belgium 17 November 2015 – One year after laying the first stone of its production and development platform’s1 in Flémalle, near the future biologistic center of Bierset airport and close to the University of Liège, Mithra Pharmaceuticals provides an update on this huge construction. The progress of the construction suggests more promising perspectives than expected

Download the press release.